Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia

NCT03808168 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped FDA has withdrawn the IND application- requesting protocol changes

Conditions

Cervix Uteri--Diseases

Interventions

DRUG: Nivolumab

Sponsor

University of Texas Southwestern Medical Center